VYNE Therapeutics Inc. (VYNE) News
Filter VYNE News Items
VYNE News Results
|Loading, please wait...|
Latest VYNE News From Around the Web
Below are the latest news stories about VYNE Therapeutics Inc that investors may wish to consider to help them evaluate VYNE as an investment opportunity.
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared to the lowest commercially available oral alternative Findings from Phase 1b safety portion of study support trial continuation Topline Phase 2a results expected in Q1 2022 BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics I
Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline)
BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. T
Investors need to pay close attention to for VYNE Therapeutics (VYNE) stock based on the movements in the options market lately.
Good morning, investor!
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), VYNE Therapeutics (VYNE) and Stoke Therapeutics (STOK)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Summit Therapeutics (SMMT – Research Report), VYNE Therapeutics (VYNE – Research Report) and Stoke Therapeutics (STOK – Research Report). Summit Therapeutics (SMMT) In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Summit Therapeutics. The company's shares closed last Friday at $5.00, close to its 52-week low of $4.55. According to TipRanks.com, Arce is a 4-star analyst with an average return of -8.2% and a 28.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
GCP Applied Technologies (GCP) stock is rising higher on Monday thanks to a massive $2.3 billion buyout deal from Saint-Gobain.
Restaurant stocks are on the move Monday and we're diving into today's news to give traders all the details on why that's happening.
VYNE Therapeutics (VYNE) stock price predictions are heating up on Monday with one analyst setting a high goal for the company to reach.
Welcome back, trader!